Literature DB >> 26202692

Increased plasma neopterin levels are associated with reduced endothelial function and arterial elasticity in hypertension.

Y-Y Zhang1,2, X-Z Tong1, W-H Xia1, W-L Xie1, B-B Yu1, B Zhang1, L Chen2, J Tao1.   

Abstract

Inflammation has been shown to play a pivotal role in the pathogenesis and development of hypertensive vascular injury. Neopterin is a novel marker of immune activation produced mainly by activated macrophages. Few data are available to show the association between neopterin and vascular function in hypertension. The present study was designed to investigate the relationship between neopterin levels related to arterial stiffness and endothelial function in patients with hypertension, and their changes after blood pressure-lowering treatment. Twenty-four hypertensive patients and 30 age- and gender-matched healthy volunteers were recruited. Plasma neopterin levels were higher in hypertensive patients compared with their counterparts (log-neopterin: 0.77±0.18 versus 0.61±0.16, P=0.003). Increased neopterin levels were correlated with increased brachial-ankle pulse wave velocity (baPWV; control: r=0.659, P<0.001; hypertension: r=0.487, P=0.021), and inversely associated with impaired brachial flow-mediated dilation (FMD; control: r=-0.735, P<0.001; hypertension: r=-0.557, P=0.005). Fifteen hypertensives received 3 months of standard antihypertensive treatment. Three months later, their plasma neopterin levels decreased (log-neopterin: 0.63±0.17 versus 0.50±0.19, P=0.001), whereas arterial elasticity (baPWV: 1764±101 versus 1685±96 cm s(-1), P=0.272) and endothelial function (FMD: 5.92±1.43% versus 7.73±1.31%, P<0.05) were improved. The decline in neopterin levels was linearly correlated with baPWV decrease (r=0.800, P<0.001), FMD improvement (r=0.670, P=0.006) and blood pressure reduction (r=0.548, P=0.042). Our present study demonstrated for the first time that neopterin is closely correlated with vascular dysfunctions, and measurement of plasma neopterin levels might be used as a surrogate biomarker for the clinical evaluation of vascular damage and risk stratification of future atherosclerotic cardiovascular disease in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202692     DOI: 10.1038/jhh.2015.72

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  24 in total

1.  Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Authors:  Stephane Laurent; John Cockcroft; Luc Van Bortel; Pierre Boutouyrie; Cristina Giannattasio; Daniel Hayoz; Bruno Pannier; Charalambos Vlachopoulos; Ian Wilkinson; Harry Struijker-Boudier
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

2.  Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction.

Authors:  Luigi Giusto Spagnoli; Elena Bonanno; Alessandro Mauriello; Giampiero Palmieri; Antonietta Partenzi; Giuseppe Sangiorgi; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

3.  Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.

Authors:  Pablo Avanzas; Ramon Arroyo-Espliguero; Juan Quiles; Debashis Roy; Juan Carlos Kaski
Journal:  Eur Heart J       Date:  2005-01-31       Impact factor: 29.983

Review 4.  Endothelial function. From vascular biology to clinical applications.

Authors:  Dominik Behrendt; Peter Ganz
Journal:  Am J Cardiol       Date:  2002-11-21       Impact factor: 2.778

Review 5.  Flow-mediated dilatation.

Authors:  O T Raitakari; D S Celermajer
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

6.  Arterial elasticity identified by pulse wave analysis and its relation to endothelial function in patients with coronary artery disease.

Authors:  J Tao; D-H Liu; L-C Wang; J-M Wang; Y Wang; Z Yang; Z-F Lou; A-L Tang
Journal:  J Hum Hypertens       Date:  2006-11-02       Impact factor: 3.012

7.  Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Juan Carlos Kaski; Luciano Consuegra-Sanchez; Daniel J Fernandez-Berges; Jose M Cruz-Fernandez; Xavier Garcia-Moll; Jaume Marrugat; Jose Mostaza; Rocio Toro-Cebada; José Ramón González-Juanatey; Gabriela Guzmán-Martínez
Journal:  Atherosclerosis       Date:  2008-03-11       Impact factor: 5.162

8.  Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients.

Authors:  J-M Wang; C Su; Y Wang; Y-J Huang; Z Yang; L Chen; F Wu; S-Y Xu; J Tao
Journal:  J Hum Hypertens       Date:  2008-11-27       Impact factor: 3.012

Review 9.  Functional and structural alterations of large arteries: methodological issues.

Authors:  Elisabetta Bianchini; Chiara Giannarelli; Rosa Maria Bruno; Sabina Armenia; Linda Landini; Francesco Faita; Vincenzo Gemignani; Stefano Taddei; Lorenzo Ghiadoni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  1 in total

1.  Relationship between neutrophil/lymphocyte ratio and epicardial fat tissue thickness in patients with newly diagnosed hypertension.

Authors:  Mehmet Ali Derya; Vahit Demir; Huseyin Ede
Journal:  J Int Med Res       Date:  2018-01-14       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.